1,791 Shares in Glaukos Co. (NYSE:GKOS) Acquired by Mount Yale Investment Advisors LLC

Mount Yale Investment Advisors LLC purchased a new stake in Glaukos Co. (NYSE:GKOS) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 1,791 shares of the medical instruments supplier’s stock, valued at approximately $212,000.

Several other hedge funds also recently added to or reduced their stakes in GKOS. Primecap Management Co. CA boosted its holdings in shares of Glaukos by 43.9% in the 2nd quarter. Primecap Management Co. CA now owns 1,220,815 shares of the medical instruments supplier’s stock valued at $144,483,000 after buying an additional 372,180 shares in the last quarter. Norges Bank purchased a new stake in Glaukos in the fourth quarter valued at $28,807,000. Allspring Global Investments Holdings LLC boosted its stake in Glaukos by 148.3% in the second quarter. Allspring Global Investments Holdings LLC now owns 412,376 shares of the medical instruments supplier’s stock valued at $48,805,000 after acquiring an additional 246,322 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new position in shares of Glaukos during the fourth quarter worth about $15,065,000. Finally, Iron Triangle Partners LP increased its position in shares of Glaukos by 75.6% during the first quarter. Iron Triangle Partners LP now owns 429,525 shares of the medical instruments supplier’s stock worth $40,500,000 after purchasing an additional 184,919 shares in the last quarter. 99.04% of the stock is currently owned by hedge funds and other institutional investors.

Glaukos Price Performance

Shares of NYSE:GKOS opened at $127.75 on Wednesday. The company has a market cap of $6.43 billion, a P/E ratio of -44.36 and a beta of 1.03. The company has a 50-day moving average price of $125.02 and a 200 day moving average price of $112.28. Glaukos Co. has a 52 week low of $59.22 and a 52 week high of $136.60. The company has a quick ratio of 4.67, a current ratio of 5.48 and a debt-to-equity ratio of 0.19.

Glaukos (NYSE:GKOS) last posted its quarterly earnings results on Wednesday, July 31st. The medical instruments supplier reported ($0.52) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.52). Glaukos had a negative net margin of 47.39% and a negative return on equity of 22.51%. The business had revenue of $95.70 million for the quarter, compared to analysts’ expectations of $88.86 million. During the same period in the prior year, the company posted ($0.55) EPS. The business’s revenue for the quarter was up 19.0% on a year-over-year basis. Research analysts predict that Glaukos Co. will post -2.18 earnings per share for the current year.

Insider Buying and Selling at Glaukos

In other news, Director Aimee S. Weisner sold 25,000 shares of the business’s stock in a transaction that occurred on Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the sale, the director now owns 30,119 shares of the company’s stock, valued at approximately $3,614,280. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. In other Glaukos news, Director Gilbert H. Kliman sold 3,000 shares of the firm’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $130.67, for a total transaction of $392,010.00. Following the completion of the transaction, the director now directly owns 32,336 shares in the company, valued at approximately $4,225,345.12. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Aimee S. Weisner sold 25,000 shares of Glaukos stock in a transaction dated Thursday, August 8th. The stock was sold at an average price of $120.00, for a total transaction of $3,000,000.00. Following the transaction, the director now owns 30,119 shares of the company’s stock, valued at approximately $3,614,280. The disclosure for this sale can be found here. Over the last three months, insiders sold 41,500 shares of company stock valued at $5,099,000. Corporate insiders own 6.40% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently issued reports on the company. Citigroup cut Glaukos from a “buy” rating to a “neutral” rating and upped their target price for the company from $130.00 to $132.00 in a research report on Wednesday, July 10th. Piper Sandler raised their target price on shares of Glaukos from $110.00 to $140.00 and gave the stock an “overweight” rating in a research report on Thursday, August 1st. BTIG Research upped their price target on shares of Glaukos from $131.00 to $139.00 and gave the company a “buy” rating in a research report on Wednesday, August 28th. Truist Financial reissued a “buy” rating and set a $145.00 price objective (up from $141.00) on shares of Glaukos in a research report on Thursday, August 1st. Finally, Stifel Nicolaus upped their target price on shares of Glaukos from $130.00 to $145.00 and gave the company a “buy” rating in a report on Tuesday, September 3rd. One analyst has rated the stock with a sell rating, three have issued a hold rating and eight have assigned a buy rating to the stock. Based on data from MarketBeat, Glaukos has an average rating of “Moderate Buy” and an average target price of $129.82.

Glaukos Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.